HER2Bi armed activated T-cells

HER2Bi armed activated T-cells are a form of adoptive cell therapy in which a patient's peripheral blood T lymphocytes are harvested, activated (typically with OKT3 and interleukin-2), then armed in vitro with a bispecific antibody (HER2Bi) that recognizes both CD3 on T cells and HER2/neu on tumor cells. This dual specificity allows the T cells to target and latch onto HER2-positive tumor cells, promoting targeted cytotoxicity. The therapy acts by cross-linking T cells to HER2-expressing tumor cells, leading to recruitment and activation of cytotoxic T lymphocytes that release perforin and cytokines such as IFN-γ, TNF-α, and IL-2, resulting in tumor cell lysis and additional immune activation. The approach is being developed primarily for HER2-positive cancers, including metastatic breast cancer, castration-resistant prostate cancer, and bladder cancer resistant to chemotherapy. HER2Bi-armed T cell therapies are under investigation in combination with checkpoint inhibitors such as pembrolizumab as well[2][3][6][8].

Other names

HER2 bispecific antibody-armed activated T cellsHER-2 bispecific antibody-armed activated T cellsHER 2 bispecific antibody-armed activated T cellsAnti-CD3 x Anti-HER2 bispecific antibody-armed T cellsAnti-CD-3 x Anti-HER2 bispecific antibody-armed T cellsAnti-CD 3 x Anti-HER2 bispecific antibody-armed T cells